Additional information
by Mohammad Asif (Author)
The focus on HIV therapy has changed during the last ten years. Long-term treatment of HIV infection is now the norm in industrialised nations because to an expanding selection of effective, practical novel medicines and co-formulations. Because of this, maintaining the efficacy of the treatment has become dependent on tolerance and side-effect control.
The majority of those who are infected do not have access to HIV and AIDS medications and therapies because anti-retroviral drugs are pricey. Antiviral medications are linked to a wide variety of adverse responses, metabolic issues, and toxicity, and research is ongoing to reduce the negative effects of currently available medications.
Although these medications frequently lack the appropriate pharmacokinetics characteristics, they have great pharmacodynamics characteristics. As a result, it becomes vital to boost pharmacokinetics using the existing methods, such as enhancing lipophilicity and GIT permeability, developing innovative drug delivery systems, and including bio-enhancer in the formulation or dietary supplement. This strengthens the legal basis for choosing a bio-enhancer in the quest to change pharmacokinetic characteristics and reduce toxicity. Those with HIV infection can now live considerably longer with recovered immunity and economy thanks to the alteration in the formulation (using a bio-enhancer) of medications causing notable adverse reactions.
